BYD-AUTO
12.1.2023 15:03:33 CET | Business Wire | Press release
BYD, the global leading new energy vehicle (NEV) manufacturer, presented its new luxury model BYD Seal and the limited edition of BYD ATTO 3 in its iconic color Forest Green at the Indian Auto Expo 2023. BYD Seal, whose sales have exceeded 50,000 within 5 months in China, is planned to be launched in India by Q4 2023. As the All-New e6 and BYD ATTO 3 are already available in the local market, BYD Seal will be the third passenger EV released in India within two years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005445/en/
Speech by Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles, BYD India (Photo: Business Wire)
At the Auto Expo 2023, BYD’s display space is sectioned into 4 zones, which showcase not only its current and new vehicle products but also technological innovations that substantially enhance the performance and safety of vehicles. These newly-unveiled products and innovation displays echo the Indian-specific theme at the convention: Technological Innovations For A Better Life.
BYD SEAL
BYD Seal is one of BYD’s latest luxury sedans equipped with its renowned EV platform (e-Platform 3.0) and revolutionary ultra-safe Blade Battery. Also, it is the first vehicle equipped with CTB (cell to body) technology, substantially upgrading the vehicle’s safety, stability, and handling, giving the vehicle an overall finer performance.
CTB-supported BYD Seal can withstand the 50-ton heavy-duty truck rolling test. Via the integration of battery and body, the torsional stiffness of the whole vehicle has doubled to above 40,500 N.m/°. The safety of the interior structure of the vehicle is increased by 50% for the front impact and by 45% for the side impact. Also, as CTB technology makes it possible for BYD Seal to have an ideal 50:50 axle load distribution, the vehicle passed the moose test at a record speed of 83.5km/h. With its low-lying design, the aero drag coefficient reached as low as 0.219cd, helping BYD Seal hit 100 km/h in 3.8 seconds. The model also has an ultra-long range of up to 700 km on a single charge, reducing the range anxiety of EVs.
BYD ATTO 3 Limited Edition
At the event, the Limited Edition of BYD ATTO 3 in the exclusive color of Forest Green, also adopts the e-Platform 3.0 and the ultra-safe Blade Battery. Only 1,200 units of this Limited Edition will be available in India at Rs. 34.49 lakhs (ex-showroom).
BYD ATTO 3, with an NEDC-certified range of 480 km and ARAI test range of 521 km, was launched in India in November 2022 for Rs. 33.99 lakhs and garnered 1,500 bookings to date, gaining good traction among customers. BYD ATTO 3 received a five-star safety rating from Euro NCAP, Europe’s leading independent safety assessment program. The E-SUV boasts an 8-year or 1.6 lakh kilometer (whichever comes earlier) warranty for the battery and a similar 8-year or 1.5 lakh kilometer warranty for the motor and motor controller. Besides, BYD offers a 6-year or 1.5 lakh kilometer basic warranty.
Sanjay Gopalakrishnan, Senior Vice President of Electric Passenger Vehicles of BYD India, said: “The Indian Auto Expo is an extremely significant platform for us, and we are pleased to be able to showcase our products and technologies through our technological innovations for a better life. With the unveiling of the electric luxury sedan BYD Seal, the launch of the Limited Edition of BYD ATTO 3, and the display of the Blade Battery, e-Platform 3.0, we resonate our commitment to contribute to the growth of the Indian electric vehicle segment with EV technologies.”
Within a year, BYD has expanded its network to 24 showrooms across 21 cities in India and will double the presence to 53 showrooms within 2023. “Next year, we plan to sell 15,000 units of BYD ATTO 3 and All-New e6 with a long-term vision to take up 40% of the Indian EV market by 2030. The bookings of BYD ATTO 3 have been encouraging, and we are all set to start the first deliveries from January 2023,” added Mr. Gopalakrishnan.
In 2022, BYD's cumulative sales of passenger vehicles were over 1.86 million units, a year-on-year increase of 155.1%. So far, BYD has sold more than 3.37 million new energy vehicles. With its expanding global presence, BYD is working towards its initiative of “Cool the Earth by 1 °C.”
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom